New York: Pfizer Pfizer, in a statement on Monday announced a study to explore co-administration of its pneumococcal vaccine along with a third dose of the Pfizer-BioNTech Covid-19 vaccine in older adults.
It said, "the first enrolled subjects have received their immunizations as part of a new study in adults ages 65 or older exploring the coadministration of the company's 20-valent pneumococcal conjugate vaccine (20vPnC) candidate following a booster dose of the Pfizer-BioNTech Covid-19 vaccine, currently authorized by the Food and Drug Administration (FDA) under an emergency use authorization (EUA)". The trial aims to describe safety when both vaccines are co-administered, with follow-up six months after vaccination and to describe immune responses produced by each of the vaccines.
The trial will include 600 adults who will be recruited from the pivotal Phase 3 Pfizer-BioNTech Covid-19 vaccine trial and will have received their second dose of the vaccine at least six months prior to entering the co-administration study.
Pfizer CEO Albert Bourla had announced that Covid vaccine recipients will "likely" need a third dose between six to 12 months after they're fully vaccinated. The company is now testing a third booster shot of its vaccine on fully vaccinated people.
Boosters and new versions of vaccines that target the Covid variants are already being explored by both Pfizer and Moderna.
Himachal Pradesh CM inaugurates 250-bed makeshift hospital near Dharamsala
Bihar extends lockdown till June 1, new guidelines to be issued soon
